Stock Events

Quince Therapeutics 

$0.69
24
-$0.03-3.61% Friday 20:00

Statistics

Day High
0.72
Day Low
0.69
52W High
1.43
52W Low
0.51
Volume
23,059
Avg. Volume
159,214
Mkt Cap
29.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

1
NOV
Earnings
 

Earnings

1NovExpected
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Next
-0.31
-0.21
-0.1
0
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QNCX. It's not an investment recommendation.
Alphabet
77857
GOOGL
Apple
67841
AAPL
Microsoft
63250
MSFT
Amazon
59029
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics, Inc. competes in the development of genomic therapies addressing a range of genetic disorders, similar to Quince Therapeutics' focus on regenerative medicines.
Bluebird bio
BLUE
Mkt Cap108.22M
Bluebird bio, Inc. is involved in gene therapies for severe genetic diseases and cancer, overlapping with Quince's therapeutic areas.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics AG focuses on the development of gene-based medicines, including therapies for genetic diseases, competing in the same innovative healthcare space as Quince.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine, Inc. works on editing genes to treat genetic diseases, directly competing with Quince's approach to addressing genetic disorders.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics, Inc. is a leading developer of CRISPR/Cas9 gene-editing therapies for genetic diseases, making it a direct competitor in the genetic medicine field.
Voyager Therapeutics
VYGR
Mkt Cap357.74M
Voyager Therapeutics, Inc. specializes in the development of gene therapies for neurodegenerative diseases, competing in the broader market of genetic disorder treatments.
Adverum Biotechnologies
ADVM
Mkt Cap144.36M
Adverum Biotechnologies, Inc. focuses on gene therapy candidates for ocular and rare diseases, which places it in competition with Quince's regenerative and genetic disorder therapies.
Protagonist Therapeutics
PTGX
Mkt Cap2.53B
Protagonist Therapeutics, Inc. is engaged in the discovery and development of novel peptide-based drugs, which could compete with Quince's therapeutic approaches in a broader sense.
Fate Therapeutics
FATE
Mkt Cap417.93M
Fate Therapeutics, Inc. is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, competing in the innovative treatment space.
Regenxbio
RGNX
Mkt Cap603.95M
REGENXBIO Inc. focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy, which competes with Quince's focus on regenerative medicine and genetic therapies.

About

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Show more...
CEO
Employees
32
Country
US
ISIN
US22053A1079

Listings

NASDAQ
US
QNCX